Preview

Вопросы современной педиатрии

Расширенный поиск

Антибиотик-ассоциированные диареи: проблемы и решения

Аннотация

В обзоре литературы освещены современные представления о механизмах развития антибиотик-ассоциированных диарей, рассмотрены особенности течения данного состояния в зависимости от этиологических факторов, основные принципы диагностики и направления лечебной тактики. Цель авторов — привлечь внимание клиницистов всех специальностей к данной проблеме.
Ключевые слова: антибиотик-ассоциированные диареи, Clostridium difficile, диагностика, терапия.

Об авторах

О.И. Ныркова
Санкт-Петербургская государственная педиатрическая медицинская академия


М.К. Бехтерева
Санкт-Петербургская государственная педиатрическая медицинская академия


А.С. Кветная
НИИ детских инфекции Федерального медико-биологического агентства России, Санкт-Петербург


Л.И. Железова
НИИ детских инфекции Федерального медико-биологического агентства России, Санкт-Петербург


Список литературы

1. Kim K.H., Fekety R., Batts D.H. et al. Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic–associated colitis. J. Infect. Dis. 1981; 143: 42–50.

2. Turck D., Bernet J.P., Marx J. et al. Incidence and risk factors of oral antibiotic associated diarrhea in an outpatient pediatric population. J. Pediatr. Gastroenterol. Nutr. 2003; 37 (1): 22–26.

3. Wistrom J., Northy S. et al. Frequency of autibiotic associated diarrhea in 2462 antibiotic-treated hospitalized patients a prospective study. J. Antimicrob. Chemother. 2001; 47: 48–50.

4. Acar J.F. A comparison of side effects of levofloxacin to other agents concerning the ecological and microbiological effects on normal human flora. Chemother. 2001; 47 (3): 15–23.

5. Golledge C.L., Carson C.F., Oneill G.L. et al. Ciprofloxacin and Clostridium difficile-associated diarrhoea. J. Antimicrob. Chemother. 1992; 30: 141–147.

6. Boenning D.A., Fleisher G.G., Campos J.M. et al. Clostridium difficile in a pediatric outpatient population. Pediatr. Infect. Dis. 1982; 1: 336–338.

7. Малов В.А. Антибиотик–ассоциированные диареи. Клин. микробиол. 2002; 4 (1): 185–197.

8. Ивашкин В.Т., Шептулин А.А., Склянская О.А. Синдром диареи. М.: ГЭОТАР–Медиа. 2002. 168 с.

9. Корниенко Е.В. Механизмы воздействия антибиотиков на кишечник, роль энтерола в профилактике и лечении антибиотик-ассоциированной диареи у детей. Фарматека. 2002; 10: 33–37.

10. Лузина Е.В. Антибиотик-ассоциированная диарея. Сибирский медицинский журнал. 2009; 2: 122–124.

11. Белоусова Е.А., Златкина А.Р. Синдром диареи в практике гастроэнтеролога: патофизиология и дифференцированный подход к лечению. Фарматека. 2003; 10: 65–71.

12. Парфенов А.И., Ручкина И.Н., Осипов Г.А. Коррекция микрофлоры кишечника пробиотиками у больных антибиотик-ассоциированной диареей. Справочник поликлинического врача. 2006. С. 2.

13. Шульпекова Ю.О. Антибиотик–ассоциированная диарея. РМЖ. 2007; 15 (6): 1–6.

14. Bartlett J.G. Antubiotic–associated diarrhea. N. Engl. J. Med. 2002; 346: 334–339.

15. Barbut F., Petit J.C. Epidemiology of Clostridium difficile nosocomial infections. Presse Med. 1996; 25 (8): 385–392.

16. Корниенко Е.А. Современные принципы выбора пробиотиков. Детские инфекции. 2007; 3: 64-69.

17. Лобзин Ю.В., Захаренко С.М., Иванов Г.А. Современные представления об инфекции Clostridium difficile. Клин. микробиол. и антимикроб. химиотер. 2002; 3: 200–232.

18. Stark P.L., Lee A., Parsonage B.D. Colonization of the large bowel by Clostridium difficile in healthy infants: quantitative study. Infect. Immun. 1982; 35: 895–899.

19. Hell M., Sickau K., Chmelizek G. et al. Absence of Clostridium difficile stool carriage in asymptomatic volunteers. FMC. Proceedings. 2011; 5 (6): 183.

20. Frost F., Craun G.F., Calderon R.L. Increasing hospitalizacion and death possibly due to Clostridium difficile diarrheal disease. EID. 1998; 4 (3): 619–625.

21. Hirschorn L.R., Trnka Y., Onderdonk A. et al. Epidemiology of community-acquired Clostridium difficile associated diarrhea. J. Infect. Dis. 1994; 169: 127–133.

22. Dubberke E.R., Butler A.M., Reske K.A. et al. Attributable outcomes of endemic Clostridium difficile associated disease in nonsurgical patients. Emerg. Infect. Dis. 2008, 14: 1031–1038.

23. Kuntz J.L., Chrischilles E.A., Pendergast J.F. et al. Incidence of and risk factors for community–associated Clostridium difficile infection: A nested case control study. BMC. Infectious. Dis. 2011; 11: 194.

24. Loo V.G., Poirier L., Miller M.A. et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile–associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 2005; 353: 2442–2449.

25. Nelson R. Antibiotics for treatment Clostridium difficile-associated diarrhea at adults. Kokranovsky Database Syst. Rev. Release 3. 2007. CD004610.

26. Парфенов И.А., Ручкина И.Н., Осипов Г.А. Антибиотик-ассоциированная диарея и псевдомембранозный колит. Consilium Medicum. 2002; 2: 24–27.

27. Pepin J., Saheb N., Coulombe M.S.A. et al. Emergence of Fluoroquinolones as the Predominant Risk Factor for Clostridium difficile–associated diarrhea: A Cohort Study during an Epidemic in Quebec. Clin. Infect. Dis. 2005; 41: 1254–1260.

28. Goorhuis A., Bakker D., Corver J. et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clinical Infectious Diseases. 2008; 47: 1162–1170.

29. Stabler R.A., He M., Dawson L. et al. Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium. Genome Biology. 2009; 10: 102.

30. Brazier J.S., Patel B., Pearson A. Distribution of Clostridium difficile PCR ribotype 027 in British hospitals. Euro. Surveil. 2007; 12 (4): 070426.

31. Cartman S.T., Heap J.T., Kuehne S.A. et al. The emergence of hypervirulence in Clostridium difficile. Int. J. Med. Microbiol. 2010; 300 (6): 387–395.

32. Kuijper E.J., Coignard B., Tüll P. ESCMID Study Group for Clostridium difficile. EU Member States, European Centre for Disease Prevention and Control: Emergence of Clostridium difficile–associated disease in North America and Europe. 2007.

33. Surawicz M.C., Elmer G.W., Speelman P. et al. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology. 1989; 96: 981–988.

34. Surawicz M.C., McFarland L.V., Greenberg R. et al. Prevention of beta lactam associated diarrhea by Saccharomyces boulardii compared with placebo. Am. J. Gastroenterol. 1995; 90: 439-438.

35. Бельмер С.В. Антибиотик–ассоциированный дисбактериоз кишечника. РМЖ. 2004; 12 (3): 148–151.

36. Teasley D.G., Gerding D.N., Olson M.N. et al. Prospective randomized trial of metronidazole versus vancomicin for Clostridium difficile associated diarrhea and colitis. Lancet. 1983; 2: 1043–1046.

37. Daniels J., Pristas A. Successful treatment of Clostridium difficile colitis with ciprofloxacin. J. Clin. Gastroenterol. 1992; 15: 176–177.

38. Dion Y.M., Richards G.K., Prentis J.J. et al. The influence of oral versus parenteral preoperative metronidazole on sepsis following colon surgery. Ann. Surg. 1980; 192: 221–226.

39. Bolton R.P., Culshaw M.A. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut. 1986; 27: 1169–1172.

40. Wenisch C., Parschalk B., Hasenhundl M. et al. Comparison of vancomycin, teicoplanin, metronidazole and fusidic acid for the treatment of Clostridium difficile associated diarrhea. Clin. Infect. Dis. 1996; 22: 813-818.

41. Department of Health. Clostridium difficile infection: how to deal with the problem. Scand. J. Infect. Dis. 2009; 41: 158–159.

42. URL:http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_093220 (accessed 11th February 2009).

43. Cloud J., Kelly C. The renewed information about Clostridium difficile connected illnesses. Curr. OPIN Gastroenterol. 2007; 23: 4–9.

44. Buggy B.P., Fekety R., Silva J. Therapy of relapsing Clostridium difficile–associated diarrhea and colitis with the combination of vancomycin and rifampin. J. Clin. Gastroenterol. 1987; 9: 155–159.

45. Lagrotteria D., Holmes S., Smieja M. et al. Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile–associated diarrhea. Clin. Infect. Dis. 2006; 43: 547–552.

46. Blossom D.B., McDonald L.K. The problems connected with reviving Clostridium difficile infection. Clin. Infect. Dis. 2007; 45 (2): 222–227.

47. McFarland L.V. Alternative methods of treatment for Clostridium difficile infection. Med. Microbiol. 2005; 54: 101.

48. Маев И.В., Самсонов А.А., Голубев Н.Н. Антибиотик–ассоциированная диарея. Consilium medicum. 2007; 9 (1).

49. Cremonini F., Di Caro S., Nista E.C. et al. Meta-analysis: the effect of probiotic administration on antibiotic–associated diarrhea. Aliment. Pharmacol. Ther. 2002; 16: 1461–1467.

50. D′Souza A., Rajkumar C., Cooke J. et al. Probiotics in prevention of antibiotic-associated diarrhea: meta–analysis. BMJ. 2002; 324 (8): 1361.

51. McNalty C., Logan M., Donald I.P. et al. Successful management Clostridium difficile infections at elderly therapies by use restrictive a policy antibiotic. J. Antimicrob. Chemother. 1997; 40: 707–711.

52. Larson H.E. Barclay F.E., Honour P. et al. Epidemiology of Clostridium difficile in infants. J. Infect. Dis. 1982; 146: 727–733.


Для цитирования:


Ныркова О., Бехтерева М., Кветная А., Железова Л. Антибиотик-ассоциированные диареи: проблемы и решения. Вопросы современной педиатрии. 2011;10(5):54-62.

For citation:


Nyrkova O., Bekhtereva M., Kvetnaya A., Zhelezova L. ANTIBIOTIC-ASSOCIATED DIARRHEA. PROBLEMS AND SOLUTIONS CONTINUOUS PROFESSIONAL EDUCATION. Current Pediatrics. 2011;10(5):54-62.

Просмотров: 202


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1682-5527 (Print)
ISSN 1682-5535 (Online)